Skin Cancer

Published Date : Sep 2023
Category : Oncology
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

The Service Framework for Skin Cancer

“Evaluating the Intricacies of Skin Cancer: Embracing Life Changing Benefits and Analysing Market Pyramid”

Skin cancer is the most prevalent condition and has become a major public health problem because of a greater understanding of consequences and socioeconomic impacts. According to World Cancer Research Fund International, the 17th most prevalent cancer globally is melanoma of the skin. However, it ranks 15th among cancers in women and 13th among cancers in men as a result of prevalence. NCI states that the total estimated cases of skin cancer in 2023 are 97,610 in the world and the number is increasing day by day.

Skin Cancer is referred to as the malignant division of skin cells. The common symptoms of skin cancer include discolored skin patches, dry skin, open sores, lesions or ulcers, peeling skin, rashes, red, white, or pus-filled bumps, and scaly or rough skin.

However, the number of cases of skin cancer is increasing worldwide. World Cancer Research Fund International states that in 2020, there were approximately 18.1 million cases of cancer reported out of which 9.3 million cases are of men and 8.8 million cases are of women. Out of the total cancer cases, 150,000 cases account for skin cancer. Men are two times as likely as women to have Skin Cancer as stated by NHS.

Overexposure to sunlight, particularly when sunburn and blisters are present, is the primary cause of skin cancer. Based on NIH data, the UVA  type of rays are the most common rays from the sun and measure for 90% of total rays that cause DNA damage in the skin. Damaged DNA leads to the formation of aberrant cells.

Skin Cancer is divided into two types which include melanoma skin cancer and non–melanoma skin cancer. According to NIH, about 75% to 80% of non-melanoma skin malignancies in people with fair skin are basal cell carcinomas, while up to 25% are squamous cell carcinomas. NIH report states that around 30,000 patients died due to melanoma and nonmelanoma skin cancers in 2018.

Furthermore, basal cell carcinoma occurs in the head and neck region. However, approximately 80% of skin cancer develops from these cells.  In addition to that, squamous cell carcinoma is mainly caused by sun exposure and occurs on lips, outside the mouth skin, vagina, and anus. Roughly, 20% of cancer cases emerge from these cells. However, 2% to 5% of squamous cell carcinoma moves to the other body parts.

Melanoma Skin Cancer is the uncountable growth of melanocytes present at the intermediate region between the dermis and epidermis. It is a dangerous type of cancer and approximately 1% of all skin cancers are melanoma skin cancer.

The number of skin cancer cases differs from region to region. Non-melanoma skin cancer mortality from these skin malignancies has decreased recently in the United States. According to the American Cancer Society (ACS), the number of deaths each year from basal cell and squamous cell skin cancer is projected to be around 2,000. Where mortality rate in the US due to melanoma cancer is reported to be 7,990 in 2023. And 4,480 persons are expected to die from other, less frequent kinds of skin cancer in 2023.

In addition to that, based on data from the Skin Cancer Foundation, due to evolution and new technology, the average five-year survival rate for melanoma patients in the US is 94% across all stages. For individuals whose melanoma is found early, the predicted five-year survival rate is over 99 percent stated by ACS. Also, ACS reports that, when the disease spreads to the lymph nodes, the survival rate drops to 71%, and when it spreads to distant organs, it reduces to 32%.

However, skin cancers have a greater mortality risk for older persons and those with weakened immune systems. In the UK incidence of Skin Cancer is around 147,000 per year as reported by NHS.

Moreover, the risk factors for skin cancer are inherited deficiencies in DNA repair processes, family history, burnt skin, immune system-suppressing medications, and arsenic exposure. The WHO provides various preventive measures like wearing UV-protecting clothes, using sunscreens, and discontinuing smoking. People should follow preventive measures to reduce the risk of getting Skin Cancer.

The market for skin cancer is affected by many factors such as high prevalence, and no early detection kits. The sector is expanding significantly due to the increased frequency of medical conditions worldwide and the difficulties in determining the underlying causes of disease development.

Currently, the early detection of skin cancer is essential. The cost-efficient, fewer side effects causing treatment therapy introduction is also important in the skin cancer landscape. This brings many opportunities for market players to invest in this sector and gain new business value. 

DiseaseLandscape Insights facilitates making informed choices in the field of medical technology, treatments, and diagnostics where different technologies and revolutionary advancements transform the landscape leading to higher growth.

Diagnostic Analysis

“From Early Diagnosis to Healthy Perfection”

Diagnosis of Skin Cancer depends on the type of disease, signs, and symptoms of patients, age, physical health, and the medical history of the patient. Greater than 75% of skin cancer cases are identified by family or patients themselves.

Roughly, 2000 Americans are diagnosed with Merkel cell cancer per year. This figure has been steadily climbing over the previous few decades. The disease affects a substantial percentage of adults over the age of 70, with White people accounting for 90% of all diagnoses.

The following diagnostic technique is performed to detect skin cancer in the patients.

  1. Skin Biopsy

A biopsy is frequently the only type of test required to diagnose and determine the stage, or extent, of cancer. A biopsy is the surgical removal of a microscopical portion of tissue for examination. The suspected skin lesion is excised during this treatment, generally after a local anesthetic has been given to numb the region. Skin biopsy takes about 2 to 3 weeks to obtain the results. However, according to 2017-2019 estimates, approximately 2.2% of men and women have been diagnosed by biopsy with melanoma of the skin at some point in their lives.

There are different types of biopsies performed to diagnose skin cancer. Incisional biopsy is in which a small piece of abnormal mass is removed by a surgical knife and tested for skin cancer. However, in an excisional biopsy, the whole abnormal area is removed and tested for skin cancer.

Diagnostic tests are frequently carried out in public laboratories that are equipped with the appropriate and occasionally pricey equipment as well as staff members who are highly qualified to carry out the tests. The market for skin cancer diagnosis is highly crowded, and many industry players are providing their input in this field.

Industry players have opportunities to develop low-cost, accurate, and fast novel biopsy techniques by using technology and immense research. Developments and evolution in diagnostic techniques raise the standard of key players.

Below are the names of market competitors who are transforming healthcare with their advanced diagnostic approaches and their products are listed below.

Market Player


Integra LifeSciences

Integra® Meshed Bilayer Wound Matrix

World Precision Instruments

E-Z Anesthesia®


Paramount Surgimed Limited

Biopsy punch

Jai Surgicals Ltd.


Innovia Medical

DTR Medical® Adson Bipolar Forceps

Cardinal Health Inc.


KAI Group

Disposable Biopsy Punch With Plunger

Becton, Dickinson, and Company

TruGuide™ Disposable Coaxial Biopsy Needle


Skin Cancer Treatment Analysis

“Succeeding Effective Health: Analyzing New Evolution in Skin Cancer Treatment”

The cases of Skin Cancer are increasing across the globe. Various treatment options are available in the market, but many researchers are working on novel therapies to treat Skin Cancer completely. However, According to statistics from the Medical Expenditure Panel Survey, over 6.1 million individuals receive treatment for basal cell and squamous cell carcinomas annually, at a cost of about $8.9 billion.

The following are the treatment options available in the market.

  1. Surgery

Surgery is a medical technique in which the tumor and surrounding tissue are removed. A fast surgical treatment allows for the rapid and simple removal of many skin malignancies. Frequently, no additional therapy is required. There are various types of surgery used to treat skin cancer which include Mohs micrographic surgery, Wide excision, Reconstructive surgery, and Sentinel lymph node biopsy. The type of surgery used depends upon the type of Skin Cancer and the size and area of lesions.

According to NIH, Mohs surgery, which has a cure rate of up to 99%, is a preferred therapy for high-risk skin cancer. This is the most minimal recurring rate of any other skin cancer therapy.

  1. Radiation Therapy

Radiation therapy destroys cancerous cells by using high-energy rays. For skin cancer that is difficult to cure, such as on the eyelid, the tip of the nose, or the ear, radiation treatment may be used instead of surgery.  Finally, radiation therapy is suggested post-surgery, particularly for lymph nodes involved in the malignancy, to prevent the skin cancer from recurring.

For stage I and II Merkel cell carcinoma, radiation treatment is commonly given after surgery. This is known as adjuvant treatment. Radiation treatment is not advised for patients with nevoid basal cell carcinoma syndrome. Radiation therapy side effects include a rash, skin infections, itchy or irritated skin, or a change in skin tone. These adverse effects, however, can generally be mitigated by applying a corticosteroid or antibiotic to the skin.

  1. Photodynamic Therapy

This is a combined therapy for actinic keratoses. First, a topical drug known as Aminolaevulinic Acid (Levulan) is applied to locations having a high number of actinic keratoses. The region is then subjected to particular light-emitting equipment for a few minutes to several hours. Because aminolevulinic acid causes skin sensitivity, the process might be painful.

  1. Chemotherapy

Chemotherapy is the use of drugs to kill cancer cells, primarily by stopping cancer cells from multiplying, growing, and dividing. These medications are often administered to the skin every day for many weeks in the treatment of skin cancer. This is known as topical therapy. These drugs cause skin inflammation or irritation, which usually goes away once the therapy is completed.

However, topical Imiquimod (Aldara, Zyclara), which activates the immune system, is indicated for tiny basal cell cancers that are not on the face. The cream must be administered once daily, five days a week, for six to twelve weeks.

  1. Targeted Therapy

The type of cancer treatment known as targeted therapy attacks certain genes, proteins, or the tissue environment that supports the growth and survival of cancer. This kind of therapy inhibits cancer cell development and spread while protecting healthy cells.

Different cancers have different targets. The physician orders tests to determine the genes, proteins, and other components in the cancer cells in order to choose the best course of therapy.

  1. Immunotherapy

Immunotherapy enhances the immune system's capacity to target cancer cells to fight the disease. Immunotherapy shows a variety of adverse effects. Immunomodulators like Cemiplimab and Pembrolizumab frequently cause side symptoms such as fatigue, discomfort, decreased appetite, itching, nausea, diarrhea, rash, fever, cough, shortness of breath, and constipation. Avelumab frequently causes side effects such as tiredness, discomfort, nausea, rash, diarrhea, and edema as a result of fluid retention.

There are multiple opportunities for business firms in the realm of the skin cancer treatment market. The market players focus on the production of diverse cost-effective therapy products, as well as the redevelopment of current medicines via the use of new technologies to enhance patient health while increasing the profit of the company.

DiseaseLandscape Insights provides extensive research on the treatment domain of skin cancer disease to keep the stakeholders one step ahead in the market. DLI equips the knowledge about treatment options, novel drugs and techniques, products, and service contributions. DLI also offers extensive research on the competitors who are in the treatment domain and developing new treatment options for better health of patients.

The global skin cancer treatment market is highly competitive and owns a large market player with a global presence. The below table shows the market player who is reshaping the domain of skin cancer and driving innovations to improve healthcare outcomes along with their product names.

Treatment Market Player


Bristol-Myers Squibb Company

Nivolumab and relatlimab-rmbw

Fougera Pharmaceuticals Inc.

Diclofenac (Solaraze)

Sarabhai Piramal Pharmaceuticals Ltd.

Fluorouracil (Adrucil)

LEO Pharma

Ingenol mebutate (Picato)

3M Company

Imiquimod (Aldara, Zyclara)


Vismodegib (Erivedge)


Sonidegib (Odomzo)

Regeneron Pharmaceuticals, Inc.

Cemiplimab (Libtayo)


Pembrolizumab (Keytruda)


Avelumab (Bavencio)

MacroGenics, Inc.

Retifanlimab (Zynyz)


Regulatory Framework for Skin Cancer –

“Regulatory Program: Ensuring a Better Working Environment”

DiseaseLandscape Insights sorts the regulatory criteria from several nations for Skin Cancer. DLI offers empirical findings regarding risk assessment, monitoring, and regulatory adherence. Organizations and market participants can prevent, manage, and react to flare-ups of Skin Cancer and protect the safety of affected people by exploring the DiseaseLandscape Insights services.

However, Nivolumab and relatlimab-rmbw were approved by the Food and Drug Administration on March 18, 2022, for use in adult and pediatric patients with metastatic or unresectable melanoma who are 12 years of age or older.

Moreover, on Jan 25, 2022, FDA approved the drug called KIMMTRAK to treat uveal melanoma which is a very rare type of cancer. 5 people per million have a chance of getting melanoma. It should only be used for individuals whose cancer cannot be surgically removed or has spread to other bodily areas.

In addition to that, the U.S. Food and Drug Administration (FDA) has also authorized Topical Fluorouracil for the treatment of extremely thin basal cell carcinomas. It needs to be administered twice daily for three to six weeks.

Competitive Analysis

"Setting up Establishments with a Skilled Lead in the Skin Cancer Market"

Several international industries are concentrating on manufacturing new products and enhancing the use of technology to improve current processes to increase their level of competition. Companies are also concentrating on ways to expand their product offerings, most commonly through collaborations, and regulatory approval for new drugs, medical research, and devices.

Competitors like Alpha Tau Medical LTD. are researching on skin cancer treatment domain. The research is in the clinical trial phase. The research is on the diffusion of alpha radiation emitters for the treatment of malignant cutaneous tumors. The development of such products has increased the awareness of diseases and products in public. Such innovations help to improve the health of patients and also increase the economy of the company.

In addition to that, a company like Amgen in collaboration with ONSEdge is working on EGFR inhibitor therapy for Skin Cancer treatment. New developments in such therapy have increased the standard of the company and gave hope for patients suffering from Skin Cancer to get a cure faster with fewer side effects.

DiseaseLandscape Insights (DLI) helps the stakeholders to stay stronger in the domain of Skin Cancer by providing in-depth knowledge of existing market players, their innovations, plans of work, growth structures, and collaborations and helps in selecting the proper position to grow continuously.

Market Trends

“Plot a Route to the Market Dynamics to Expand the Business”.

The market for Skin Cancer is growing worldwide because there is a need for the development of various cost-efficient diagnostic techniques and innovations in new treatment products for the complete cure of Skin Cancer. In-depth research is required to formulate new therapies and other treatment options for Skin Cancer.

However, researchers are working in the treatment industry to cure patients completely with fewer possible side effects. Gene–modified immune cells are the treatment option available in the market. Innovations in such therapy are trending in the market. Key players have opportunities in the treatment field to improve patient health and expand their business globally.

Moreover, increased R&D in the sector is another insight that is expected to promote growth in the industry. To treat specific kinds of basal cell or squamous cell skin malignancies, Northampton General Hospital NHS Trust radiologists and researchers developed Skin Brachytherapy in December 2021. Market players have tremendous scope in the Skin Brachytherapy field of Skin Cancer to withstand with strong foot and generate huge revenue.

All in all, manufacturing diagnostic kits, developing innovative therapies, and producing new medicines have increased market size and, consequently, the revenue of current key players. The establishment of rules and regulations in the research industry, government efforts for patient health, and innovative technologies have all increased the market's impact.

Clinical Trial Data Assessment

The government's increased emphasis on comparing the effectiveness of studies highlights the essential importance of clinical trials in the practice of evidence-based medicine and health care reform. One of the main aims of healthcare reform is realized by market participants thoroughly assessing medical therapy using clinical data.

The table below includes the study names of the ongoing clinical trials at phase I, II, and III.

Phase I

Phase II

Phase III

Treatment of Skin Tumours With Intratumoral Interleukin 12 Gene Electrotransfer in the Head and Neck Region

A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment

The Role Of Tumescence In Split Thickness Skin Grafting For Reconstruction Of Head And Neck Cancer Resection

Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility Study

A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma

A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda® in Patients With Unresectable or Metastatic Melanoma

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors

A Randomized, Placebo-controlled, Double-blind, Phase II Chemoprevention Clinical Trial of Topical Diclofenac and DFMO in Subjects With a History of Skin Cancer

A Personalized Approach to Skin Cancer Prevention Among Adolescents

Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Non-melanoma Skin Cancers

A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

Risk Information and Skin-Cancer Education and Undergraduate Prevention Trial

Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases


A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High-Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study

A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.



DiseaseLandscape Insights (DLI) recognizes the critical importance of understanding the disease, particularly when it comes to fighting skin cancer. DLI's comprehensive services are intended to help the healthcare sector, its professionals, researchers, and other industry participants improve patient outcomes while strengthening and expanding their businesses.

By harnessing the power of extensive market research, our services provide invaluable insights into the latest advancements, treatment techniques, and emerging trends in skin cancer management. This enables healthcare professionals to make informed decisions, devise targeted strategies, and deliver personalized care to patients. Moreover, our services serve as a catalyst for collaboration and innovation, fostering partnerships among industry stakeholders and researchers to drive advancements in Skin Cancer treatment and prevention.

This allows market leaders to do concentrated R&D, learn about contract manufacturing organizations, discover raw material suppliers, and assure legal compliance for the business.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape